Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Kidney International

Volumn 93, Issue 1, 2018, Pages 231-244

  Cherney, David Z I ^a   Cooper, Mark E ^b   Tikkanen, Ilkka ^c   Pfarr, Egon ^d   Johansen, Odd Erik ^e   Woerle, Hans J ^d   Broedl, Uli C ^d   Lund, Søren S ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Boehringer Ingelheim Norway KS   (Norway)

Author keywords

diabetic nephropathy; glomerular filtration rate; kidney diseases; SGLT2 inhibition

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREND STUDY; URINARY TRACT INFECTION; WEIGHT REDUCTION; AGED; BLOOD; BLOOD PRESSURE; BODY WEIGHT LOSS; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD PRESSURE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOWN-REGULATION; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; KIDNEY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85028413629     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.06.017     Document Type: Article

References (39)

1. Musso, G., Gambino, R., Cassader, M., Pagano, G., A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44 (2012), 375–393.
2. Chen, J., Williams, S., Ho, S., et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1 (2010), 57–92.
3. Heise, T., Jordan, J., Wanner, C., et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther 38 (2016), 2265–2276.
4. Perkins, B.A., Cherney, D.Z., Partridge, H., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
5. Haring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
6. Haring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
7. Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
8. Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
9. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 (2015), 2117–2128.
10. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375 (2016), 323–334.
11. Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
12. Macha, S., Mattheus, M., Halabi, A., et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 16 (2014), 215–222.
13. Agarwal, N., Rice, S.P., Bolusani, H., et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 95 (2010), 722–730.
14. Kim, S.G., Ryu, O.H., Kim, H.Y., et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol 154 (2006), 433–440.
15. Kiyici, S., Ersoy, C., Kaderli, A., et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 86 (2009), 44–50.
16. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
17. Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
18. Mansour, A.S., Yannoutsos, A., Majahalme, N., et al. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens 31 (2013), 1584–1592.
19. Cardoso, C.R., Ferreira, M.T., Leite, N.C., Salles, G.F., Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study. Diabetes Care 36 (2013), 3772–3778.
20. Theilade, S., Lajer, M., Persson, F., et al. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 36 (2013), 715–721.
21. Cooper, J.N., Buchanich, J.M., Youk, A., et al. Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms. Atherosclerosis 223 (2012), 485–490.
22. Samaras, K., Viardot, A., Lee, P.N., et al. Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: the role of immune cell activation and insulin resistance. Diab Vasc Dis Res 10 (2013), 40–48.
23. Rosenstock, J., Jelaska, A., Zeller, C., et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 17 (2015), 936–948.
24. Rosenstock, J., Jelaska, A., Frappin, G., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
25. Nishimura, R., Tanaka, Y., Koiwai, K., et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol, 14, 2015, 11.
26. Brands, M.W., Manhiani, M.M., Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol 303 (2012), R1101–R1109.
27. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
28. Heise, T., Jordan, J., Wanner, C., et al. Acute pharmacodynamic effects of empagliflozin with and without diuretics in patients with type 2 diabetes. Clin Ther 38 (2016), 2248–2264.
29. Mancia, G., Cannon, C.P., Tikkanen, I., et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes and hypertension by background antihypertensive medication. Hypertension 68 (2016), 1355–1364.
30. Luzardo, L., Noboa, O., Boggia, J., Mechanisms of salt-sensitive hypertension. Curr Hypertens Rev 11 (2015), 14–21.
31. Petrykiv, S., Sjostrom, C.D., Greasley, P.J., et al. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Clin J Am Soc Nephrol 12 (2017), 751–759.
32. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16 (2014), 1016–1027.
33. Strazzullo, P., Barbato, A., Vuotto, P., Galletti, F., Relationships between salt sensitivity of blood pressure and sympathetic nervous system activity: a short review of evidence. Clin Exp Hypertens 23 (2001), 25–33.
34. Meng, L., Fu, B., Zhang, T., et al. Salt sensitivity of blood pressure in non-dialysis patients with chronic kidney disease. Ren Fail 36 (2014), 345–350.
35. Jordan, J., Tank, J., Heusser, K., et al. Empagliflozin has no discernable effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight. Diabetes, 63(suppl 1), 2014, A265.
36. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
37. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86 (2014), 1057–1058.
38. Lund-Johansen, P., Effects of antihypertensive therapy on the hemodynamics of hypertension: clinical implications. Clin Ther 8 (1986), 382–397.
39. Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.